MedTrace Logo

Endoscopic Prevention of Esophageal Cancer at Tenwek Hospital

NCT02146508 · Status: SUSPENDED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2023-12-11

No results posted yet for this study

Summary

Esophageal cancer is common in Kenya. The precursor of esophageal cancer is esophageal squamous dysplasia (ESD). In this study, persons known to have ESD will undergo endoscopic removal or ablation of ESD in order to prevent development of esophageal cancer.

Conditions

  • Esophageal Cancer
  • Esophageal Squamous Dysplasia

Interventions

PROCEDURE

Endoscopic Mucosal Resection (EMR)

Endoscopic removal of regions of ESD.

DEVICE

Radiofrequency ablation

Endoscopic radiofrequency ablation of regions of ESD

Sponsors & Collaborators

  • Mayo Clinic

    collaborator OTHER

  • National Cancer Institute (NCI)

    collaborator NIH

  • Medtronic - MITG

    collaborator INDUSTRY

  • Tenwek Hospital

    lead OTHER

Principal Investigators

  • Stephen L Burgert, MD · Tenwek Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2024-07-31
Completion
2024-07-31

Countries

  • Kenya

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02146508 on ClinicalTrials.gov